A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort.
<h4>Purpose</h4> <p>About 60% of ovarian cancers are diagnosed at late stage, when5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian canc...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for Cancer Research
2016
|
| _version_ | 1826257070077247488 |
|---|---|
| author | Terry, K Schock, H Fortner, R Hüsing, A Fichorova, R Yamamoto, H Vitonis, A Johnson, T Overvad, K Tjønneland, A Boutron-Ruault, M Mesrine, S Severi, G Dossus, L Rinaldi, S Boeing, H Benetou, V Lagiou, P Trichopoulou, A Krogh, V Kuhn, E Panico, S Bueno-de-Mesquita, H Onland-Moret, N Peeters, P Gram, I Weiderpass, E Duell, E Sanchez, M Ardanaz, E Etxezarreta, N Navarro, C Idahl, A Lundin, E Jirström, K Manjer, J Wareham, N Khaw, K Smith Byrne, K Travis, R Gunter, M Merritt, M Riboli, E Cramer, D Kaaks, R |
| author_facet | Terry, K Schock, H Fortner, R Hüsing, A Fichorova, R Yamamoto, H Vitonis, A Johnson, T Overvad, K Tjønneland, A Boutron-Ruault, M Mesrine, S Severi, G Dossus, L Rinaldi, S Boeing, H Benetou, V Lagiou, P Trichopoulou, A Krogh, V Kuhn, E Panico, S Bueno-de-Mesquita, H Onland-Moret, N Peeters, P Gram, I Weiderpass, E Duell, E Sanchez, M Ardanaz, E Etxezarreta, N Navarro, C Idahl, A Lundin, E Jirström, K Manjer, J Wareham, N Khaw, K Smith Byrne, K Travis, R Gunter, M Merritt, M Riboli, E Cramer, D Kaaks, R |
| author_sort | Terry, K |
| collection | OXFORD |
| description | <h4>Purpose</h4> <p>About 60% of ovarian cancers are diagnosed at late stage, when5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best source of information to evaluate early detection biomarkers. Here we evaluate the most promising ovarian cancer screening biomarkers in prospectively collected samples from the European Prospective Investigation into Cancerand Nutrition study.</p> <h4>Experimental Design</h4> <p>We measured CA125, HE4, CA72.4 and CA15.3 in 810 invasive epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% specificity as well as Area under the Receiver Operator Curve (C-statistic) for each marker individually and in combination. Additionally, we evaluated marker performance by stage at diagnosis and time between blood draw and diagnosis. </p> <h4>Results</h4> <p>We observed the best discrimination between cases and controlswithin six months of diagnosis for CA125 (C-statistic=0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). Marker performance declined with longer time between blood draw and diagnosis and for earlier staged disease. However, assessment of discriminatory ability at early stage was limited by small numbers. Combinations of markers performed modestly, but significantly better than any single marker. </p> <h4>Conclusions</h4> <p>CA125 remains the single best marker for the early detection of invasive epithelial ovarian cancer, but can be slightly improved by combining with other markers. Identifying novel markers for ovarian cancer will require studies including larger numbers of early stage cases. </p> |
| first_indexed | 2024-03-06T18:12:17Z |
| format | Journal article |
| id | oxford-uuid:03700a7e-3e18-4811-8299-a3ba3fb88ec0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:12:17Z |
| publishDate | 2016 |
| publisher | American Association for Cancer Research |
| record_format | dspace |
| spelling | oxford-uuid:03700a7e-3e18-4811-8299-a3ba3fb88ec02022-03-26T08:46:16ZA prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:03700a7e-3e18-4811-8299-a3ba3fb88ec0EnglishSymplectic Elements at OxfordAmerican Association for Cancer Research2016Terry, KSchock, HFortner, RHüsing, AFichorova, RYamamoto, HVitonis, AJohnson, TOvervad, KTjønneland, ABoutron-Ruault, MMesrine, SSeveri, GDossus, LRinaldi, SBoeing, HBenetou, VLagiou, PTrichopoulou, AKrogh, VKuhn, EPanico, SBueno-de-Mesquita, HOnland-Moret, NPeeters, PGram, IWeiderpass, EDuell, ESanchez, MArdanaz, EEtxezarreta, NNavarro, CIdahl, ALundin, EJirström, KManjer, JWareham, NKhaw, KSmith Byrne, KTravis, RGunter, MMerritt, MRiboli, ECramer, DKaaks, R<h4>Purpose</h4> <p>About 60% of ovarian cancers are diagnosed at late stage, when5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best source of information to evaluate early detection biomarkers. Here we evaluate the most promising ovarian cancer screening biomarkers in prospectively collected samples from the European Prospective Investigation into Cancerand Nutrition study.</p> <h4>Experimental Design</h4> <p>We measured CA125, HE4, CA72.4 and CA15.3 in 810 invasive epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% specificity as well as Area under the Receiver Operator Curve (C-statistic) for each marker individually and in combination. Additionally, we evaluated marker performance by stage at diagnosis and time between blood draw and diagnosis. </p> <h4>Results</h4> <p>We observed the best discrimination between cases and controlswithin six months of diagnosis for CA125 (C-statistic=0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). Marker performance declined with longer time between blood draw and diagnosis and for earlier staged disease. However, assessment of discriminatory ability at early stage was limited by small numbers. Combinations of markers performed modestly, but significantly better than any single marker. </p> <h4>Conclusions</h4> <p>CA125 remains the single best marker for the early detection of invasive epithelial ovarian cancer, but can be slightly improved by combining with other markers. Identifying novel markers for ovarian cancer will require studies including larger numbers of early stage cases. </p> |
| spellingShingle | Terry, K Schock, H Fortner, R Hüsing, A Fichorova, R Yamamoto, H Vitonis, A Johnson, T Overvad, K Tjønneland, A Boutron-Ruault, M Mesrine, S Severi, G Dossus, L Rinaldi, S Boeing, H Benetou, V Lagiou, P Trichopoulou, A Krogh, V Kuhn, E Panico, S Bueno-de-Mesquita, H Onland-Moret, N Peeters, P Gram, I Weiderpass, E Duell, E Sanchez, M Ardanaz, E Etxezarreta, N Navarro, C Idahl, A Lundin, E Jirström, K Manjer, J Wareham, N Khaw, K Smith Byrne, K Travis, R Gunter, M Merritt, M Riboli, E Cramer, D Kaaks, R A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. |
| title | A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. |
| title_full | A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. |
| title_fullStr | A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. |
| title_full_unstemmed | A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. |
| title_short | A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. |
| title_sort | prospective evaluation of early detection biomarkers for ovarian cancer in the european epic cohort |
| work_keys_str_mv | AT terryk aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT schockh aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT fortnerr aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT husinga aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT fichorovar aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT yamamotoh aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT vitonisa aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT johnsont aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT overvadk aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT tjønnelanda aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT boutronruaultm aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT mesrines aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT severig aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT dossusl aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT rinaldis aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT boeingh aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT benetouv aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT lagioup aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT trichopouloua aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT kroghv aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT kuhne aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT panicos aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT buenodemesquitah aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT onlandmoretn aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT peetersp aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT grami aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT weiderpasse aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT duelle aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT sanchezm aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT ardanaze aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT etxezarretan aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT navarroc aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT idahla aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT lundine aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT jirstromk aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT manjerj aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT warehamn aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT khawk aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT smithbyrnek aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT travisr aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT gunterm aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT merrittm aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT ribolie aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT cramerd aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT kaaksr aprospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT terryk prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT schockh prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT fortnerr prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT husinga prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT fichorovar prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT yamamotoh prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT vitonisa prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT johnsont prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT overvadk prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT tjønnelanda prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT boutronruaultm prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT mesrines prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT severig prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT dossusl prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT rinaldis prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT boeingh prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT benetouv prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT lagioup prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT trichopouloua prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT kroghv prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT kuhne prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT panicos prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT buenodemesquitah prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT onlandmoretn prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT peetersp prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT grami prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT weiderpasse prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT duelle prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT sanchezm prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT ardanaze prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT etxezarretan prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT navarroc prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT idahla prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT lundine prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT jirstromk prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT manjerj prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT warehamn prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT khawk prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT smithbyrnek prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT travisr prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT gunterm prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT merrittm prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT ribolie prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT cramerd prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort AT kaaksr prospectiveevaluationofearlydetectionbiomarkersforovariancancerintheeuropeanepiccohort |